Latest Insider Transactions at Spring Works Therapeutics, Inc. (SWTX)
This section provides a real-time view of insider transactions for Spring Works Therapeutics, Inc. (SWTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of SpringWorks Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of SpringWorks Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 19
2022
|
Freda C Lewis Hall Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,818
+44.85%
|
-
|
|
May 19
2022
|
Julie Hambleton Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,818
+44.85%
|
-
|
|
May 19
2022
|
Alan Fuhrman Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,818
+44.85%
|
-
|
|
May 19
2022
|
Daniel Lynch Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,818
+1.6%
|
-
|
|
May 19
2022
|
Stephen P Squinto Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,818
+3.53%
|
-
|
|
May 19
2022
|
Jeffrey Lawrence Schwartz Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,818
+44.85%
|
-
|
|
Apr 01
2022
|
Bhavesh Ashar Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,464
-5.73%
|
$81,984
$56.9 P/Share
|
|
Jan 07
2022
|
Badreddin Edris Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,531
-0.77%
|
$141,736
$56.06 P/Share
|
|
Jan 07
2022
|
Saqib Islam Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,893
-0.69%
|
$330,008
$56.06 P/Share
|
|
Jan 07
2022
|
L. Mary Smith Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,772
-0.93%
|
$99,232
$56.06 P/Share
|
|
Jan 07
2022
|
Michael Nofi Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
567
-6.48%
|
$31,752
$56.06 P/Share
|
|
Jan 07
2022
|
Perier I Francis Jr Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,846
-6.41%
|
$103,376
$56.06 P/Share
|
|
Jan 07
2022
|
Daniel Pichl Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
842
-3.78%
|
$47,152
$56.06 P/Share
|
|
Jan 07
2022
|
Herschel S Weinstein General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
1,323
-6.59%
|
$74,088
$56.06 P/Share
|
|
Jan 06
2022
|
Michael Nofi Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,748
+39.65%
|
-
|
|
Jan 06
2022
|
Bhavesh Ashar Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,062
+33.82%
|
-
|
|
Jan 06
2022
|
Michael F. Burgess Head of Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
15,674
+26.63%
|
-
|
|
Jan 06
2022
|
Daniel Pichl Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,062
+36.94%
|
-
|
|
Jan 06
2022
|
Herschel S Weinstein General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
13,062
+39.43%
|
-
|
|
Jan 06
2022
|
L. Mary Smith Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,205
+10.48%
|
-
|
|
Jan 06
2022
|
Perier I Francis Jr Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,809
+39.5%
|
-
|
|
Jan 06
2022
|
Badreddin Edris Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,124
+7.38%
|
-
|
|
Jan 06
2022
|
Saqib Islam Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
78,370
+8.37%
|
-
|
|
Oct 20
2021
|
Saqib Islam Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,083
-1.28%
|
$584,814
$58.67 P/Share
|
|
Oct 19
2021
|
Saqib Islam Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
14,077
-1.8%
|
$816,466
$58.81 P/Share
|
|
Oct 18
2021
|
Saqib Islam Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
38,340
-4.67%
|
$2,223,720
$58.59 P/Share
|
|
Oct 13
2021
|
L. Mary Smith Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-5.63%
|
$550,000
$55.97 P/Share
|
|
Oct 13
2021
|
L. Mary Smith Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.33%
|
$20,000
$2.3 P/Share
|
|
Sep 08
2021
|
Daniel Pichl Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,320
+20.08%
|
$99,760
$43.1 P/Share
|
|
Aug 10
2021
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,000,000
-17.15%
|
$70,000,000
$70.25 P/Share
|
|
Jul 20
2021
|
Saqib Islam Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,572
-2.21%
|
$1,430,044
$77.68 P/Share
|
|
Jul 19
2021
|
Saqib Islam Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
43,928
-4.97%
|
$3,338,528
$76.09 P/Share
|
|
Jul 13
2021
|
L. Mary Smith Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-5.63%
|
$800,000
$80.88 P/Share
|
|
Jul 13
2021
|
L. Mary Smith Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.33%
|
$20,000
$2.3 P/Share
|
|
Jul 01
2021
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
15,959
-0.26%
|
$1,356,515
$85.01 P/Share
|
|
Jul 01
2021
|
Badreddin Edris Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
32,000
-9.59%
|
$2,720,000
$85.35 P/Share
|
|
Jun 28
2021
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
6,502
-0.11%
|
$552,670
$85.17 P/Share
|
|
Jun 25
2021
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
22,334
-0.37%
|
$1,898,390
$85.14 P/Share
|
|
Jun 24
2021
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
34,200
-0.56%
|
$2,907,000
$85.22 P/Share
|
|
Jun 23
2021
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
100
-0.0%
|
$8,500
$85.0 P/Share
|
|
Jun 10
2021
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
30,852
-0.5%
|
$2,622,420
$85.09 P/Share
|
|
Jun 09
2021
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,049
-0.08%
|
$429,165
$85.33 P/Share
|
|
Jun 08
2021
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
42,633
-0.69%
|
$3,623,805
$85.37 P/Share
|
|
Jun 07
2021
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
371
-0.01%
|
$31,164
$84.9 P/Share
|
|
Jun 01
2021
|
Michael F. Burgess Head of Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+50.0%
|
-
|
|
May 20
2021
|
Jeffrey Lawrence Schwartz Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,106
+50.0%
|
-
|
|
May 20
2021
|
Stephen P Squinto Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,106
+0.86%
|
-
|
|
May 20
2021
|
Daniel Lynch Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,106
+0.38%
|
-
|
|
May 20
2021
|
Freda C Lewis Hall Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,106
+4.2%
|
-
|
|
May 20
2021
|
Julie Hambleton Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,106
+15.58%
|
-
|